OverviewSuggest Edit

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.
TypePublic
Founded2015
HQSouth San Francisco, CA, US
Websitedenalitherapeutics.com
Employee Ratings3.7
Overall CultureB+

Latest Updates

Employees (est.) (Dec 2019)261(+46%)
Revenue (FY, 2020)$335.7 M(+1159%)
Share Price (May 2021)$58.3(-3%)
Cybersecurity ratingAMore

Key People/Management at Denali Therapeutics

Carole Ho

Carole Ho

Chief Medical Officer
Steve Krognes

Steve Krognes

Chief Financial Officer
Cindy Dunkle

Cindy Dunkle

Chief People Officer
Dolo Diaz

Dolo Diaz

Vice President, Development Sciences
Joe Lewcock

Joe Lewcock

Chief Scientific Officer
Peter Chin

Peter Chin

Vice President, Late Clinical
Show more

Denali Therapeutics Office Locations

Denali Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
151 Oyster Point Blvd
Show all (1)

Denali Therapeutics Financials and Metrics

Denali Therapeutics Revenue

Denali Therapeutics's revenue was reported to be $335.66 m in FY, 2020
USD

Revenue (Q1, 2021)

7.9m

Net income (Q1, 2021)

(70.0m)

EBIT (Q1, 2021)

(71.2m)

Market capitalization (3-May-2021)

7.1b

Closing stock price (3-May-2021)

58.3

Cash (31-Mar-2021)

435.3m

EV

6.7b
Denali Therapeutics's current market capitalization is $7.1 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

129.2m26.7m335.7m

Sales and marketing expense

5.1m11.7m15.7m

General and administrative expense

32.3m46.5m60.3m

R&D expense

11.6m75.7m74.5m143.2m193.4m212.6m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

641.0k1.6m1.2m4.2m3.6m5.8m9.4m7.9m

General and administrative expense

5.6m6.9m8.8m9.3m12.6m14.0m15.8m18.9m

R&D expense

20.8m52.1m30.3m37.4m51.0m53.2m53.7m60.2m

Operating expense total

26.4m59.0m39.2m46.7m63.6m67.1m69.5m79.1m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

39.9m218.4m77.1m79.4m507.1m

Prepaid Expenses

3.6m3.4m16.5m14.7m20.3m

Current Assets

182.0m409.6m480.8m430.0m1.5b

PP&E

15.3m14.9m25.2m46.7m40.8m
Quarterly
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(16.8m)(86.7m)(88.2m)(36.2m)(197.6m)71.1m

Depreciation and Amortization

121.0k1.5m3.1m8.0m

Accounts Payable

1.7m161.0k207.0k(526.0k)1.0m(1.6m)

Cash From Operating Activities

(15.1m)(72.4m)(76.6m)50.1m(151.6m)416.2m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(23.7m)(78.4m)(113.8m)(39.0m)(56.8m)(115.5m)(173.7m)(70.0m)

Depreciation and Amortization

854.0k2.7m5.0m2.4m2.1m4.3m6.4m2.1m

Accounts Payable

(951.0k)7.1m1.2m2.0m(292.0k)(744.0k)147.0k623.0k

Cash From Operating Activities

33.6m(8.2m)(43.1m)(30.3m)(54.5m)(97.8m)(97.8m)(50.2m)
Show all financial metrics

Denali Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Denali Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Denali Therapeutics Online and Social Media Presence

Embed Graph

Denali Therapeutics Company Culture

  • Overall Culture

    B+

    85/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Denali Therapeutics News and Updates

Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results f…

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced final results from…

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that the U.S. Fo…

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced additional positi…

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

– Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time – – Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time –

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Nancy Thornb…
Show more

Denali Therapeutics Blogs

Denali Therapeutics at Stifel’s 3rd Annual CNS Day

Denali Therapeutics at Stifel’s 3rd Annual CNS Day cognito_kainra… Wed, 03/24/2021 - 20:55 Event Type Investor Conference Start Date Wed, 03/31/2021 - 16:00 Timezone EST End Date …

Denali Therapeutics at H.C. Wainwright Global Life Sciences Conference

Denali Therapeutics at H.C. Wainwright Global Life Sciences Conference cognito_kainra… Tue, 03/02/2021 - 00:32 Event Type Investor Conference Start Date Tue, 03/09/2021 - 07:00 Timezone EST Eve…

nancythornbeeryprofileboard

nancythornbeeryprofileboard cognito_pezzul… Mon, 01/11/2021 - 23:06 Full Name Nancy A. Thornberry Position CEO, Kallyope Biography Nancy A. Thornberry is CEO at Kallyope, a biotechnology company headquartered in…

ETV:IDUA

ETV:IDUA cognito_effenb… Fri, 01/08/2021 - 15:58 Alpha-L-iduronidase (IDUA) is an enzyme responsible for degrading heparan and dermatan sulfate in the lysosome. Genetic defects in IDUA result in a reduction or absence of lysosomal IDUA activity and cause Hurler syndrome (or MPS I), whi…

Denali Therapeutics Frequently Asked Questions

  • When was Denali Therapeutics founded?

    Denali Therapeutics was founded in 2015.

  • Who are Denali Therapeutics key executives?

    Denali Therapeutics's key executives are Carole Ho, Steve Krognes and Cindy Dunkle.

  • How many employees does Denali Therapeutics have?

    Denali Therapeutics has 261 employees.

  • What is Denali Therapeutics revenue?

    Latest Denali Therapeutics annual revenue is $335.7 m.

  • What is Denali Therapeutics revenue per employee?

    Latest Denali Therapeutics revenue per employee is $1.3 m.

  • Who are Denali Therapeutics competitors?

    Competitors of Denali Therapeutics include Sema4, GenePlanet and Orchard Therapeutics.

  • Where is Denali Therapeutics headquarters?

    Denali Therapeutics headquarters is located at 151 Oyster Point Blvd, South San Francisco.

  • Where are Denali Therapeutics offices?

    Denali Therapeutics has an office in South San Francisco.

  • How many offices does Denali Therapeutics have?

    Denali Therapeutics has 1 office.